Evogene (EVGN) Q4 2025 earnings review
Radical Restructuring Saves Cash but Decimates Top Line
Evogene is executing a drastic pivot. Management is effectively liquidating or sidelining its entire legacy portfolio of subsidiaries (Lavie Bio, Biomica, Casterra) to bet the company's future solely on its 'ChemPass AI' computational discovery platform. While this ruthless restructuring successfully reduced FY25 operating expenses by 37% YoY, it has also caused core revenues to collapse. Q4 revenue decelerated to a meager $314k, and a severe $2.2M inventory impairment at the previously hyped Casterra subsidiary pushed quarterly gross margins deeply into negative territory. The company's balance sheet is currently sustained by divestiture proceeds rather than operational cash flow.
🐂 Bull Case
The company has proven it can aggressively cut costs. FY25 operating expenses dropped to $13.8M from $22.0M in FY24. Combined with cash from the Lavie Bio asset sale, Evogene has bought itself time to execute its AI strategy.
The collaboration with Google Cloud to build a generative AI foundation model trained on 38 billion structures adds significant technical credibility to the ChemPass AI platform, potentially accelerating partnership discussions with large pharma.
🐻 Bear Case
The Casterra seed business, heavily promoted earlier in the year as a near-term revenue driver, has reversed course violently. Kenya operations were ceased due to weak demand, leading to a $2.2M inventory impairment.
With its subsidiaries dismantled, Evogene is entirely dependent on securing milestone-based partnerships for ChemPass AI. If drug discovery partnerships take longer to materialize than expected, the company has no fallback revenue streams.
⚖️ Verdict: 🔴
Bearish. The transition to an asset-light, pure-play computational AI company is theoretically appealing, but executing this pivot while legacy revenues collapse and write-offs mount presents extreme execution risk.
Key Themes
ChemPass AI Pivot and Google Cloud Integration
Evogene is staking its entire future on its ChemPass AI engine. The company announced a second collaboration phase with Google Cloud in February 2026 to integrate AI agents via Vertex AI. This is designed to automate workflows and reduce manual errors in small-molecule discovery. This technological leap is the primary growth driver moving forward, aimed at capturing high-margin R&D licensing fees from pharma and ag-chem partners.
Casterra Narrative Reverses with Massive Write-Off
A major red flag emerged regarding Casterra. In Q1 2025, management highlighted record deliveries of 250 tons of castor seeds and positioned the unit as a cash cow. This narrative is reversing: due to a 'significant decline in demand,' Casterra ceased Kenyan operations, reduced headcount, and booked a $2.2M inventory impairment in Q4. This completely contradicts the earlier bullish commercialization narrative.
Aggressive Downsizing and Divestiture Windfalls
Management successfully executed a brutal but necessary downsizing. AgPlenus was integrated into the core, Canonic was shuttered, and Lavie Bio was sold to ICL. Biomica just licensed its lead oncology candidate (BMC128) to Lishan Pharmaceuticals in early 2026. The company expects Lavie Bio and Biomica to distribute their remaining cash to shareholders (including Evogene), which will act as a critical non-dilutive funding driver.
Evaporating Commercial Revenue Base
With the wind-down or divestment of its subsidiaries, Evogene's recurring revenue base is decelerating rapidly. Q4 2025 revenue was just $314k, down 80% YoY. Until new ChemPass AI partnerships are signed, the top line will remain negligible, putting immense pressure on the remaining cash reserves.
Macro Destocking Hits Ag-Chem Demand
The broader agricultural cycle and inventory destocking continue to impact the company's legacy ag-centric operations. The decline in demand for Casterra seeds is symptomatic of a tougher macro environment for agricultural inputs, which forced the company to retreat to a narrower focus in Brazil rather than expanding in Africa.
R&D Expense Rationalization
Research and development expenses are decelerating sharply as the company shifts from expensive field trials and clinical studies (Lavie Bio, Biomica) to a purely computational model. Q4 2025 R&D expenses were $1.8M, down 32% from $2.7M in Q4 2024.
Continued Reliance on Dilutive Financing
Despite cost cuts, Evogene still needs cash. In February 2026, the company entered a warrant inducement agreement resulting in $3.4M gross proceeds, but at the cost of issuing over 5 million new unregistered warrants exercisable immediately at $1.25 per share, capping potential upside for existing shareholders.
Other KPIs
Reversing sharply into negative territory. Gross profit went from $851k in 24Q4 to a massive loss of $1.97M in 25Q4. This was entirely driven by the $2.18M inventory impairment at Casterra. Without this one-time hit, underlying gross margins on the tiny remaining revenue base would have been relatively normal.
This line item single-handedly saved the company's FY25 bottom line. It reflects the sale of the majority of Lavie Bio's assets and Evogene's MicroBoost AI to ICL, which generated a $6.4 million gain on sale. This masks the severe $14.0M operating loss generated by the continuing business.
Stable compared to $15.3M at the end of 2024. Cash usage from continuing operations improved, with consolidated cash usage in Q4 at approximately $3.0M. Stripping out the legacy subsidiaries, the core Evogene AI operations used about $2.4M in Q4.
Guidance
Stable. The company did not provide explicit forward revenue guidance, but management explicitly stated that the drastically reduced Q4 expense level (approx. $3.2 million total operating expenses) 'is expected to be sustained in future periods'. This confirms the new, lower-burn profile of the computational pivot.
Management expects Lavie Bio and Biomica to distribute the majority of their remaining cash balances to shareholders (including Evogene) during 2026. This serves as an informal guidance for near-term cash injections to support the parent company's runway.
Key Questions
ChemPass AI Revenue Timeline
With legacy revenues virtually gone, what is the realistic timeline for securing the first major, cash-generating licensing deal for ChemPass AI in the pharma segment?
Casterra's Remaining Viability
After taking a $2.2M impairment and ceasing operations in Kenya due to collapsing demand, why retain Casterra and focus on Brazil rather than divesting it entirely like the other subsidiaries?
Quantifying Subsidiary Dividends
You guided that Lavie Bio and Biomica will distribute their remaining cash to shareholders in 2026. How much cash does Evogene practically expect to receive from these distributions?
Warrant Dilution Impact
The February 2026 warrant inducement raised $3.4M but added over 5 million new warrants at $1.25. How does management justify this level of dilution given the recent claims of a sufficient 18-month cash runway?